Promoter holding
64.27%
GP
Goldencross Pharma Limited - Due diligence report
A 360° intelligence report on Goldencross Pharma Limited: trust score, financial health, credit view, compliance, directors, growth and dist…
Full Due-Diligence Report + Documents
- Unlock all financial figures & 5-year trends
- Full trust, health & credit-risk scores
- Director details, charges & MCA documents
₹700
₹349
50% off
New user
Or enjoy up to 50% off with credits
View credit packages
Company Credits – Starter
- One credit unlocks this full due-diligence report
- Use across any company’s report, anytime
- Credits valid for 12 months
Choose your own credit amount
View credit packages
Goldencross Pharma Limited — 360° Intelligence Report
Generated from MCA filings & public records87/100
Trust Score
Low Risk
Goldencross Pharma Limited is assessed as Low Risk with a Trust Score of 87/100. Goldencross Pharma Limited is an active public limited indian non-government company incorporated in 2000, operating in the Pharma sector. Reported revenue has declined across its recent filed years. It was profitable in its latest filed year. Based on MCA filings and public records, it currently shows a low compliance risk and low financial risk profile.
Report generated on 03 Jul 2026 from the latest processed filings. Goldencross Pharma Limited snapshot & full profile →
Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.
02
Score Card
Higher is safer · rule-based & explainableTrust ScoreLow Risk
87/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreLow Risk
83/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreLow Risk
85/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreLow Risk
90/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreLow Risk
85/100
Board strength, DIN status, churn and network.
Growth ScoreCaution Indicated
45/100
Revenue, profit, asset and hiring momentum.
Distress ScoreLow Risk
90/100
Early-warning signals - higher means fewer warnings.
03
Financial Intelligence Dashboard
Standalone · 5 filed year(s)Unlock the full 5-year financial dashboard with charts and year-wise figures.
Get full accessScores and observations on this page are already computed from the real filings - only the underlying figures are locked.
04
Credit & Compliance Intelligence
Why the scores are what they are
Credit Risk Score: 90/100 Low Risk
- Liabilities ≈ 38% EBITDA - serviceable.
- No open charges - unencumbered balance sheet.
- Working-capital cover adequate.
- Profitable - internal accruals available.
Charges position: 0 open (-) · 3 satisfied (91.50 cr).
Banking relationships (from registered charges)
| Lender | Charges | Amount |
|---|---|---|
| The Hongkong And Shanghai Banking Corporation Limited | 1 | 48.0 cr |
| Credit Lyonnias | 2 | 48.0 cr |
Compliance Score: 83/100 Low Risk
- Company status is Active as per MCA.
- Annual filings current (balance sheet Mar 2025).
- Litigation present in 1 court forum(s).
- 1 auditor resignation(s) filed - latest: V. SANKAR AIYAR & CO on 2017-02-20.
- 4 active GST registration(s).
Legal cases on record (1)
05
Director Intelligence
Stability score: 85/100| Name | DIN / PAN | Designation | Appointed | Tenure | DIN status |
|---|---|---|---|---|---|
| PANTHA MILAN KUNDU | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| ANISHA NARESH UDESHI | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| Chirag Hotchandani | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| SWAPN BHAWANI MALPANI | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| UJJWAL PRAKASH SHENDRE | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| RAJENDRA KUMAR CHOPRA | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
- 6 directors on the board.
- No disqualified or deactivated DINs.
- 1 director exit(s) in the last 3 years.
Director & KMP remuneration (FY 2019)
| Name | Designation | Total remuneration |
|---|---|---|
| A K Sharma | Managing Director | 2.4 cr |
| R Mehta | Whole-time Director | 1.6 cr |
| S Iyer | CFO | 95.0 L |
Remuneration is disclosed in the latest annual return. Unlock full report
06
Ownership & Group Intelligence
As per FY 2023 annual returnPublic / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
Cipla Limited
Subsidiaries
-
Group entities
-
Capital events
3 allotment(s) · 4 transfer(s)
Promoters hold a dominant controlling stake - exact percentages are part of the full report.
| Group entity | Relationship | % held |
|---|---|---|
| Cipla Limited | Holding Company | 74.00% |
Key managerial personnel: PANTHA MILAN KUNDU (CFO) · UJJWAL PRAKASH SHENDRE (Managing Director)
Full shareholding pattern, group structure & capital events →
07
Risk Intelligence Center
Growth 45 · Distress 90
Growth signals & trust indicators
EPFO headcount growing - hiring signal.
Operating for 26+ years.
Active EPFO - real payroll on record.
Active GST registration(s).
Distress signals & risk flags
1 auditor resignation(s) on record - review the stated reasons.
1 court case(s) on record - see the legal section for details.
08
Stakeholder Verdicts
Vendor · Banker · InvestorVendor due diligence86/100
Favourable indicators
Suitability as a supplier / customer counterparty.
- Statutory record is clean.
- No distress signals on file.
- Financial filings available for verification.
Banker assessment87/100
Favourable lending indicators
Indicative lending comfort for banks, NBFCs and trade credit.
- Debt capacity assessed from filed statements.
- No existing security registered - first-charge position available.
- Compliance record supports lending.
Investor view70/100
Positive growth indicators
Growth quality and scalability through an investor lens.
- 1 growth signal(s) detected.
- Margin and return trends computable from filings.
- Management team looks stable.
09
MCA Filings & Events Timeline
Latest 15 events25 Sep 2025
Last AGM held
Annual general meeting
24 Sep 2025
Director ceased
SWAPN BHAWANI MALPANI
31 Mar 2025
Latest balance sheet
Filed with ROC
16 Dec 2024
Director appointed
SWAPN BHAWANI MALPANI (Director)
22 Sep 2023
Director appointed
PANTHA MILAN KUNDU (CFO)
24 May 2023
Director appointed
UJJWAL PRAKASH SHENDRE (Managing Director)
Director ceased
UJJWAL PRAKASH SHENDRE
08 Jun 2022
Director ceased
RANJANA BHUBNESWAR PATHAK
02 Feb 2022
Director appointed
Chirag Hotchandani (Company Secretary)
21 Sep 2021
Director ceased
Nishtha Agrawal
20 Jul 2021
Director ceased
ATUL YESHWANT SANT
31 Mar 2021
Share transfer (FY 2021)
1.00000000 shares to Sanjay Surendra Bhanushali
Share transfer (FY 2021)
1.00000000 shares to Mosale Suryanarayana Ramanath
18 Dec 2020
Director ceased
DINESH RAMNIRANJAN JAIN
Director ceased
SANJAY BHANUSHALI SURENDRA
10
Key Observations
Auto-generated from the data aboveRevenue declined 1.42 over the last 4 financial year(s).
Net profit margin moved from 2.1x to 24%.
Net worth is positive.
Compliance record is strong - status, filings and flags are clean.
6 active director(s) / partner(s); board looks stable and experienced.
4 active GST registration(s) indicate ongoing business operations.
All 3 registered charge(s) stand satisfied - past borrowings repaid.
EPFO-registered employer - verifiable payroll history exists.
Promoters hold a dominant controlling stake as per the FY 2023 annual return.
Director / KMP remuneration is disclosed in the latest annual return - exact figures available in the full report.
Capital has been raised through 3 security allotment(s) - amounts available in the full report.
| Company | CIN | Location |
|---|---|---|
| Panila Chem Limited | U24303GJ2017PLC096453 | Bhavnagar, Gujarat, India |
| G T Z (India) Pvt Ltd | U27109WB1973PTC029127 | Bishnupur, West Bengal, India |
| Medsource | U85100DL2003PTC120213 | New Delhi, Delhi, India |
| Cht (India) Private Limited | U24297MH1996PTC149192 | Navi Mumbai, Maharashtra, India |
| Magma Industries Limited | U24129UP1999PLC024442 | Muzaffarnagar, Uttar Pradesh, India |
| Rishabh Metals & Chemicals Private Limited | U24110MH1983PTC030239 | Mumbai, Maharashtra, India |
| Nico Orgo Marketing Private Limited | U01409GJ1998PTC033770 | Dist Kheda, Gujarat, India |
| Venor Pharma Limited | U74900DL2013PLC251565 | Delhi, Delhi, India |
12
Who Uses This Report
CA · CS · Banker · Investor · VendorChartered Accountants (CA)
Verify Goldencross Pharma Limited before audits and certifications: compliance score 83/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.
Company Secretaries (CS)
Track statutory health of Goldencross Pharma Limited: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.
Bankers & NBFCs
Current banker verdict: Favourable lending indicators. Credit risk score 90/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.
Investors & Analysts
Investor view: Positive growth indicators. Growth score 45/100, margin trends, ownership structure and peer set for Goldencross Pharma Limited - screening before a deeper diligence.
Vendors & Procurement Teams
Vendor verdict: Favourable indicators. Trust score 87/100, distress signals and MSME payment-delay disclosures - know whether Goldencross Pharma Limited pays its suppliers before you extend credit terms.
Lawyers & Compliance Teams
Litigation footprint (1 case(s) on record), regulatory flags, charge documents trail and director networks for Goldencross Pharma Limited - groundwork for KYC, onboarding and disputes.
13
Frequently Asked Questions
Is Goldencross Pharma Limited an active company?
Goldencross Pharma Limited has MCA status “Active” with a compliance score of 83/100 (Low Risk).
Is Goldencross Pharma Limited financially healthy?
Goldencross Pharma Limited has a Financial Health Score of 85/100 (Low Risk) based on its filed financial statements.
Should I do business with Goldencross Pharma Limited?
Its overall Trust Score is 87/100 (Low Risk). Vendor verdict: Favourable indicators. Review the risk flags in the Risk Intelligence Center before deciding.
Who controls Goldencross Pharma Limited?
The ultimate holding entity is Cipla Limited. 6 active director(s) are on record.
Does Goldencross Pharma Limited have loans or charges against its assets?
No open charges - all 3 registered charge(s) stand satisfied, indicating past borrowings were repaid.
Is Goldencross Pharma Limited up to date with its ROC filings?
Annual filings current (balance sheet Mar 2025). Overall compliance score: 83/100 (Low Risk).
Is it risky to lend to Goldencross Pharma Limited?
Its Credit Risk Score is 90/100 (Low Risk). Banker verdict: Favourable lending indicators.
Disclaimer: This report is generated automatically from MCA filings and public records as available
in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the
underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are
not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice.
Verify from official sources and consult a qualified professional before any business, lending or investment decision.
If you represent this company and believe any information is inaccurate or outdated,
report it here and we will review promptly.
